tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

CLDX Stock Latest News

Celldex’s Phase 3 Study on Barzolvolimab: A Potential Game-Changer for Chronic Spontaneous Urticaria
Company AnnouncementsCelldex’s Phase 3 Study on Barzolvolimab: A Potential Game-Changer for Chronic Spontaneous Urticaria
9h ago
CLDX
Celldex’s Barzolvolimab: A Promising Treatment for Eosinophilic Esophagitis with Market Potential
PremiumRatings
Celldex’s Barzolvolimab: A Promising Treatment for Eosinophilic Esophagitis with Market Potential
2d ago
CLDX
Celldex’s Phase 3 Study on Barzolvolimab: A Potential Game-Changer for Chronic Spontaneous Urticaria
PremiumCompany Announcements
Celldex’s Phase 3 Study on Barzolvolimab: A Potential Game-Changer for Chronic Spontaneous Urticaria
2d ago
CLDX
Celldex’s Promising Advancements and Strategic Growth: A Buy Rating from Analyst Sam Slutsky
PremiumRatings
Celldex’s Promising Advancements and Strategic Growth: A Buy Rating from Analyst Sam Slutsky
6d ago
CLDX
Celldex: Strong Financial Position and Promising Pipeline Drive Buy Rating Despite Risks
PremiumRatings
Celldex: Strong Financial Position and Promising Pipeline Drive Buy Rating Despite Risks
7d ago
CLDX
Celldex reports Q2 EPS (85c), consensus (84c)
PremiumThe FlyCelldex reports Q2 EPS (85c), consensus (84c)
7d ago
CLDX
CLDX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
CLDX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
10d ago
CLDX
Celldex Therapeutics’ Phase 3 Study on Barzolvolimab: A Potential Game-Changer for Chronic Urticaria
Premium
Company Announcements
Celldex Therapeutics’ Phase 3 Study on Barzolvolimab: A Potential Game-Changer for Chronic Urticaria
13d ago
CLDX
Celldex Therapeutics’ Phase 3 Study: A Potential Breakthrough for Chronic Urticaria
PremiumCompany Announcements
Celldex Therapeutics’ Phase 3 Study: A Potential Breakthrough for Chronic Urticaria
15d ago
CLDX
Celldex Therapeutics’ Promising Phase 2 Study on Barzolvolimab for Prurigo Nodularis
PremiumCompany Announcements
Celldex Therapeutics’ Promising Phase 2 Study on Barzolvolimab for Prurigo Nodularis
15d ago
CLDX
RBC downgrades Jasper Therapeutics on questions about briquilimab
PremiumThe Fly
RBC downgrades Jasper Therapeutics on questions about briquilimab
1M ago
CLDX
JSPR
Celldex Therapeutics’ Promising Phase 2 Study on Eosinophilic Esophagitis
PremiumCompany Announcements
Celldex Therapeutics’ Promising Phase 2 Study on Eosinophilic Esophagitis
2M ago
CLDX
Celldex’s Phase 3 Study on Barzolvolimab: A Potential Game-Changer for Chronic Urticaria
PremiumCompany AnnouncementsCelldex’s Phase 3 Study on Barzolvolimab: A Potential Game-Changer for Chronic Urticaria
2M ago
CLDX
Celldex Therapeutics Advances Phase 2 Study on Barzolvolimab for Prurigo Nodularis
Premium
Company Announcements
Celldex Therapeutics Advances Phase 2 Study on Barzolvolimab for Prurigo Nodularis
2M ago
CLDX
Celldex announces data on barzolvolimab from its Phase 2 trial in CSU
Premium
The Fly
Celldex announces data on barzolvolimab from its Phase 2 trial in CSU
2M ago
CLDX
Celldex’s Barzolvolimab: Promising Phase 2 Results and Market Potential Justify Buy Rating
PremiumRatings
Celldex’s Barzolvolimab: Promising Phase 2 Results and Market Potential Justify Buy Rating
2M ago
CLDX
Celldex’s Barzolvolimab Shows Promising Phase 2 Results for CSU, Earning Buy Rating
PremiumRatings
Celldex’s Barzolvolimab Shows Promising Phase 2 Results for CSU, Earning Buy Rating
2M ago
CLDX
Celldex’s Promising Barzolvolimab Results and Growth Prospects Drive Buy Rating
PremiumRatings
Celldex’s Promising Barzolvolimab Results and Growth Prospects Drive Buy Rating
2M ago
CLDX
Promising Outlook for Celldex’s Barzolvolimab: Buy Rating Affirmed Amid Competitive Edge and Upcoming Catalysts
PremiumRatings
Promising Outlook for Celldex’s Barzolvolimab: Buy Rating Affirmed Amid Competitive Edge and Upcoming Catalysts
2M ago
CLDX
Closing Bell Movers: RH jumps 20% after Q1 earnings beat
PremiumThe FlyClosing Bell Movers: RH jumps 20% after Q1 earnings beat
2M ago
RH
SUZ
Celldex says Phase 2 Barzolvolimab study met primary endpoint
Premium
The Fly
Celldex says Phase 2 Barzolvolimab study met primary endpoint
2M ago
CLDX
Celldex’s Barzolvolimab Shows Promising Long-Term Efficacy in CSU: Analyst Recommends Buy with $64 Target
Premium
Ratings
Celldex’s Barzolvolimab Shows Promising Long-Term Efficacy in CSU: Analyst Recommends Buy with $64 Target
2M ago
CLDX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >